Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

Published:2019-01-01 Issue:1 Volume:5 Page:83
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Bennouna Jaafar¹,Hiret Sandrine²,Bertaut Aurelie³,Bouché Olivier⁴,Deplanque Gael⁵,Borel Christian⁶,François Eric⁷,Conroy Thierry⁸,Ghiringhelli François³,des Guetz Gaëtan⁹,Seitz Jean-François¹⁰,Artru Pascal¹¹,Hebbar Mohamed¹²,Stanbury Trevor¹³,Denis Marc G.¹⁴,Adenis Antoine¹⁵,Borg Christophe¹⁶

Affiliation:

1. Department of Hepatogastroenterology, Digestive Oncology, Centre Hospitalier Universitaire de Nantes, Nantes, France

2. Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Saint-Herblain, France

3. Department of Medical Oncology, Georges-François Leclerc Cancer Center, Dijon, France

4. Department of Hepatogastroenterology, Centre Hospitalier Universitaire Robert Debré, Reims, France

5. Department of Medical Oncology, Hôpital Saint-Joseph, Paris, France

6. Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France

7. Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France

8. Institut de Cancérologie de Lorraine, et Vandoeuvre-Lès Nancy, Université de Lorraine, Vandoeuvre-Lès Nancy, France

9. Department of Medical Oncology, Assistance Publique–Hôpitaux de Paris, Paris, France

10. Department of Hepatogastroenterology, Digestive Oncology, Assistance Publique–Hôpitaux de Marseille La Timone, Marseille, France

11. Hôpital Privé Jean Mermoz, Lyon, France

12. Department of Medical Oncology, University Hospital, Lille, France

13. UNICANCER, Paris, France

14. Centre Hospitalier Universitaire de Nantes, Nantes, France

15. Department of Medical Oncology, Centre Oscar Lambret, Lille, France

16. Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference20 articles.

1. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.;Giantonio;J Clin Oncol,2007

2. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.;Van Cutsem;J Clin Oncol,2012

3. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.;Tabernero;Lancet Oncol,2015

4. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.;Sobrero;J Clin Oncol,2008

5. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer.;Peeters;Clin Cancer Res,2015

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer;Cancer Reports;2024-01-22

2. High‐intensity focused ultrasound ablation combined with systemic therapy for unresectable colorectal cancer liver metastasis: A propensity score‐matched analysis;Cancer Medicine;2023-11-30

3. Multi-level characteristics recognition of cancer core therapeutic targets and drug screening for a broader patient population;Frontiers in Pharmacology;2023-11-23

4. Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with pulmonary metastasis: a cohort study;European Journal of Cancer Prevention;2023-10-09

5. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16;ESMO Open;2023-10